Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds (NCT07265791) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds
100 participantsStarted 2026-01-03
Plain-language summary
Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds
Who can participate
Age range19 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 19 to 75 years
* Voluntarily provided written informed consent
* Moderate to severe symmetrical nasolabial folds (WSRS score 3 or 4 on both sides)
* Agree to discontinue other facial dermatologic treatments (e.g., fillers, botulinum toxin, laser) during the study
* Able to understand instructions and comply with study procedures
Exclusion Criteria:
* Untreated scars or facial skin infections/diseases affecting the mid/lower face within the past year
* History of severe allergy or hypersensitivity to device components
* Facial invasive procedures within the past 6 months (including surgery, laser, botulinum toxin)
* Use of certain medications (anticoagulants, immunosuppressants, steroids) within specified washout periods
* Participation in other interventional clinical trials within 4 weeks before screening or during study
* Non-compliance with contraception requirements or pregnancy/lactation during study
* Deemed unsuitable by investigator for any other reason
What they're measuring
1
AE
Timeframe: From adverse event onset through resolution or stabilization, up to 30 days post-study completion
2
SAE
Timeframe: From adverse event onset through resolution or stabilization, up to 30 days post-study completion
3
Solicited local AE
Timeframe: Within 2 weeks after device application